Emmaus Medical, Inc. Sustainability Profile
Emmaus Medical, Inc., headquartered in the United States, is a pioneering company in the biopharmaceutical industry, specialising in innovative treatments for rare diseases. Founded in 2008, Emmaus has made significant strides in developing therapies that address unmet medical needs, particularly in the field of sickle cell disease. The company’s flagship product, Endari, is a unique L-glutamine oral powder that has been clinically proven to reduce complications associated with sickle cell disease. This groundbreaking treatment has positioned Emmaus Medical as a leader in the market, with a commitment to improving patient outcomes and quality of life. With a strong operational presence across the US and expanding internationally, Emmaus Medical continues to achieve notable milestones, reinforcing its reputation as a trusted provider of specialised medical solutions.
DitchCarbon Score
How does Emmaus Medical, Inc.'s carbon action stack up? DitchCarbon scores companies based on their carbon action and commitment to reducing emissions. Read about our methodology to learn more.
Industry Average
Mean score of companies in the Pharmaceutical Preparation Manufacturing industry. Comparing a company's score to the industry average can give you a sense of how well the company is doing compared to its peers.
Industry Benchmark
Emmaus Medical, Inc.'s score of 23 is lower than 69% of the industry. This can give you a sense of how well the company is doing compared to its peers.
Let us know if this data was useful to you
Emmaus Medical, Inc.'s reported carbon emissions
Emmaus Medical, Inc., headquartered in the US, currently does not report any specific carbon emissions data, as indicated by the absence of emissions figures in kg CO2e. Furthermore, there are no documented reduction targets or climate pledges associated with the company. As a current subsidiary, Emmaus Medical, Inc. may inherit climate-related data and initiatives from its parent organisation; however, no specific details or metrics have been provided. This lack of publicly available information suggests that the company has yet to establish a clear framework for measuring or reducing its carbon footprint. In the context of the industry, it is increasingly important for companies to adopt robust climate commitments and transparent reporting practices to align with global sustainability goals. Emmaus Medical, Inc. will need to consider developing and communicating its climate strategy to meet stakeholder expectations and contribute to broader environmental efforts.
How Carbon Intensive is Emmaus Medical, Inc.'s Industry?
How Carbon Intensive is Emmaus Medical, Inc.'s Location?
Emmaus Medical, Inc.'s Climate Goals (2030 & 2050)
Climate goals typically focus on 2030 interim targets and 2050 net-zero commitments, aligned with global frameworks like the Paris Agreement and Science Based Targets initiative (SBTi) to ensure alignment with global climate goals.
Emmaus Medical, Inc. has not publicly committed to specific 2030 or 2050 climate goals through the major frameworks we track. Companies often set interim 2030 targets and long-term 2050 net-zero goals to demonstrate measurable progress toward decarbonization.
